Author | Ronald Melzack, PhD


Quality-of-Life End Points in Oncology Drug Trials

October 01, 1999

ByRonald Melzack, PhD

Measurement of the quality of life (QOL) of patients, particularly those with cancer, has recently become a major scientific endeavor. The rapid growth of the hospice movement throughout the world during the past half-century has underscored the importance of palliation when a cure no longer seems possible.